---------
If so, you may have a possible legal case against the manufacturer of the potentially dangerous drug or medical product. Simply fill out the short form below and an experienced legal expert will contact you as soon as possible!
Added August 10th, 2005
Despite the hopes of companies such as Merck and Pfizer that their cox-2 inhibitor drugs will be reintroduced back on the market at some point, the European Medicines Agency (EMEA) has confirmed that Bextra will remain banned in Europe, and that similar medications will be looked at with a view to placing more restrictions on them.
In a review of Bextra, which was performed by the European Medicines Agency recently, it was concluded that the risks associated with taking Bextra far outweighed the benefits of the drug, and therefore the decision was made to keep the ban in place. There are a number of serious side effects that have come to light about this and other cox-2 inhibitors, including heart attacks, strokes, and with Bextra a serious and potentially deadly skin disease.
It has been reported that the suspension placed on Bextra will be reviewed within a year. During this time, Pfizer is expected to produce safety information in order to support the possibility of Bextra being re-introduced to the market. However, if the supporting evidence is not forthcoming, then it is unlikely that the ban will be lifted even after another year.
Reviews are still being carried out on other cox-2 inhibitors as well as standard non steroid anti-inflammatory drugs. However, the EMEA states that it is unsure “if the findings for COX-2 inhibitors are also relevant for conventional NSAIDs.”
Bextra Ban To Remain In F | Printable Version (Opens In New Window)